Epstein-Barr virus–specific cytokine-induced killer cells for treatment of Epstein-Barr virus–related malignant lymphoma
- Sprache
-
Englisch
- Identifier
-
1162190051
Beteiligte Personen und Organisationen
Pfeffermann, Lisa-Marie
Pfirrmann, Verena
Hünecke, Sabine
Bremm, Melanie
Bönig, Halvard-Björn
Kvasnicka, Hans-Michael
Klingebiel, Thomas
Bader, Peter
Rettinger, Eva
Pfirrmann, Verena
Hünecke, Sabine
Bremm, Melanie
Bönig, Halvard-Björn
Kvasnicka, Hans-Michael
Klingebiel, Thomas
Bader, Peter
Rettinger, Eva
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:56 MEZ
Beteiligte
- Pfeffermann, Lisa-Marie
- Pfirrmann, Verena
- Hünecke, Sabine
- Bremm, Melanie
- Bönig, Halvard-Björn
- Kvasnicka, Hans-Michael
- Klingebiel, Thomas
- Bader, Peter
- Rettinger, Eva
Ähnliche Objekte (12)
Improving clinical manufacturing of IL-15 activated cytokine-induced killer (CIK) cells
In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy
Retargeting of NK-92 cells against high-risk rhabdomyosarcomas by means of an ERBB2 (HER2/Neu)-specific chimeric antigen receptor
Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience
The synergistic use of il-15 and il-21 for the generation of nk cells from cd3/cd19-depleted grafts improves their ex vivo expansion and cytotoxic potential against neuroblastoma: Perspective for optimized immunotherapy post haploidentical stem cell transplantation
Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation
Development of three different NK cell subpopulations during immune reconstitution after pediatric allogeneic hematopoietic stem cell transplantation: prognostic markers in GvHD and viral infections
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma
Joint modeling of immune reconstitution post haploidentical stem cell transplantation in pediatric patients with acute leukemia comparing CD34+-selected to CD3/CD19-depleted grafts in a retrospective multicenter study
An exponential regression model reveals the continuous development of B cell subpopulations used as reference values in children
The phenotype and functional activity of mesenchymal stromal cells in pediatric patients with non-malignant hematological disease
Improving clinical manufacturing of IL-15 activated cytokine-induced killer (CIK) cells
In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy
Retargeting of NK-92 cells against high-risk rhabdomyosarcomas by means of an ERBB2 (HER2/Neu)-specific chimeric antigen receptor
Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience
The synergistic use of il-15 and il-21 for the generation of nk cells from cd3/cd19-depleted grafts improves their ex vivo expansion and cytotoxic potential against neuroblastoma: Perspective for optimized immunotherapy post haploidentical stem cell transplantation
Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation
Development of three different NK cell subpopulations during immune reconstitution after pediatric allogeneic hematopoietic stem cell transplantation: prognostic markers in GvHD and viral infections
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma
Joint modeling of immune reconstitution post haploidentical stem cell transplantation in pediatric patients with acute leukemia comparing CD34+-selected to CD3/CD19-depleted grafts in a retrospective multicenter study
An exponential regression model reveals the continuous development of B cell subpopulations used as reference values in children
The phenotype and functional activity of mesenchymal stromal cells in pediatric patients with non-malignant hematological disease
Improving clinical manufacturing of IL-15 activated cytokine-induced killer (CIK) cells
In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy
Retargeting of NK-92 cells against high-risk rhabdomyosarcomas by means of an ERBB2 (HER2/Neu)-specific chimeric antigen receptor
Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience
The synergistic use of il-15 and il-21 for the generation of nk cells from cd3/cd19-depleted grafts improves their ex vivo expansion and cytotoxic potential against neuroblastoma: Perspective for optimized immunotherapy post haploidentical stem cell transplantation
Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation
Development of three different NK cell subpopulations during immune reconstitution after pediatric allogeneic hematopoietic stem cell transplantation: prognostic markers in GvHD and viral infections
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma
Joint modeling of immune reconstitution post haploidentical stem cell transplantation in pediatric patients with acute leukemia comparing CD34+-selected to CD3/CD19-depleted grafts in a retrospective multicenter study
An exponential regression model reveals the continuous development of B cell subpopulations used as reference values in children